Navigation Links
Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
Date:4/3/2013

WESTFORD, Mass., April 3, 2013 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) today announced the presentation of 16 scientific abstracts at LASER 2013, the 33rd Annual Scientific Conference of the American Society for Laser Medicine and Surgery (ASLMS). The clinical research includes four abstracts intended to demonstrate the safety and efficacy of the Company's PicoSure picosecond Alexandrite laser technology for aesthetic indications including the removal of tattoos and the improvement of acne scarring and stretch marks.  LASER 2013 takes place April 3-7, 2013 at the Sheraton Boston Hotel/Hynes Convention Center in Boston, Massachusetts.

"The PicoSure data being presented at LASER 2013 underscores the clinical benefits of the technology for patients seeking a safe, effective treatment with minimal downtime," said Michael Davin , Cynosure's Chairman and Chief Executive Officer. "Quite simply, PicoSure produced better results with fewer treatments than current modalities, with high levels of patient and physician satisfaction."   

PicoSure is the industry's first picosecond laser cleared for the removal of tattoos and benign pigmented lesions. The device received 510(k) clearance from the U.S. Food and Drug Administration at the end of 2012.  Cynosure is currently launching PicoSure in the United States.

Unlike longer pulse energy sources whose principal mechanism of action is photothermal or heat-producing, a picosecond laser delivers photothermal and significant photomechanical or acoustic effects.  A picosecond laser's pulse is approximately 100 times shorter than the pulse of established treatment modalities, enabling it to treat a range of aesthetic indications with less collateral tissue heating.

Key AS
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
2. Cynosure Announces Upcoming Conference Presentations
3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
8. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
9. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
10. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... data, competitor focus, and new drug-eluting technologies to drive ... according to Millennium Research Group WALTHAM, Mass., May ... European Markets for Peripheral Vascular (PV) Devices 2009 ... that treat lower extremity peripheral artery disease in Europe ...
... Results and additional analyses from the Phase II portion ... drug relaxin for the treatment of acute heart failure ... annual meeting of the Heart Failure Association of the ... Metra, M.D., professor of cardiology at the University of ...
Cached Medicine Technology:Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 2Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 3Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... University of Chicago, have been assessing the effectiveness ... which is commonly prescribed for treatment of bronchitis, ... allocated 150 adults with acute bronchitis to either ... cough syrup (liquid dextromorphan) and an albuterol inhaler. ...
... to a research, women who live at high altitudes ... after finding lower concentrations of hormones, which are important ... the mountainous areas. ,For comparison researchers looked at a ... ethnic origin who lived at just 150 m above ...
... feeding rats with black raspberries reduces the risk of colon ... fresh fruits and vegetables may reduce the risk of cancer. ... protective compounds that various types of produce contain. //The latest ... -and how they may reduce the risk of colon cancer. ...
... new research, implants to aid hearing loss are going down ... a quarter of all adults aged over 60 in the ... a hearing problem - an acoustic hearing aid. // ... middle ear which directly vibrates the surrounding bones. Researchers in ...
... men population, which evaluated more than 14,000 sperm samples, found ... numbers as well as their crucial ability to move or ... ozone level went up, the sperm concentration went down," said ... and gynecology at the University of Southern California's Keck School ...
... a gene which acts as a specific diagnostic marker ... analysis, which allows investigation of the activity of thousands ... called a-methylacyl-CoA racemase (AMACR) and it's never before been ... study, AMACR was found in over 90 per cent ...
Cached Medicine News:Health News:High Altitude ‘Speeds up ageing process 2Health News:Elevated Ozone Levels Hurt Sperm Count 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: